Mylan, Momenta take aim at Regeneron ’ s Eylea with biosimilar

Momenta Pharmaceuticals (NSDQ:MNTA) and Mylan (NSDQ:MYL) announced yesterday that they plan to launch a pivotal trial in the first half of 2018 for a proposed biosimilar to Regeneron‘s (NSDQ:REGN) blockbuster drug, Eylea.
Eylea, a VEGF-inhibitor designed to treat wet age-related macular degeneration and diabetic macular edema, has little competition on today’s market. The drug brought in more than $5 billion for Regeneron in 2016.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan, Momenta take aim at Regeneron’s Eylea with biosimilar appeared first on MassDevice.

Source: Mass Device - January 4, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat momentapharmaceuticals Mylan Regeneron Source Type: news